Metformin for the Prevention of Frailty in High Risk Older Adults
Funded by a grant from the National Institute of Health Older American Independent Center
Currently Recruiting
The purpose of the study is to find out if metformin treatment prevents or reduces frailty in older adults who are pre-diabetic. Frailty is a geriatric syndrome which leads people to falls, become disabled, require nursing home placement, and have increased risk for death.
Contact: Barshop Clinical Research Call Center | 210-450-0020
Location: 7th Floor STVHCS Audie L. Murphy VA Hospital in the Bartter Research Unit (BRU)
HEALTHY WEIGHT
Healthy Weight Intervention Among Aging Women: An Investigation into the Role of Aging on Intervention Efficacy
The funding for this study is provided by the UTHSCSA’s Institute for Integration of Medicine and Science (IIMS) and the San Antonio Claude D. Pepper Older Americans Independence Center. This organization (UTHSCSA) is providing money so that the researchers can conduct the study.
Currently Recruiting
The purpose of this study is to develop and evaluate a group program designed to help adult women improve eating behaviors and how they feel about their bodies. We also want to compare how women of different ages like and respond to the program. How women feel about themselves can impact other aspects of their lives, such as physical and mental health. So, we are also interested in the effect that participating in the study has on participants’ health and wellness behaviors, such as eating behaviors, mood, blood pressure, and participation in activities.
Contact: Meghan Curtis | 210-562-4680
METFORMIN AND IMMUNE FUNCTION
Metformin and vaccine response in older adults (ImmuneMET)
This study is funded through a grant from the National Institutes of Health/National Institute on Aging to UT Health San Antonio’s Claude D. Pepper Older Americans Independence Center so that the researchers can conduct the study.
Currently Recruiting
This study is intended to determine whether the drug metformin (MET) can improve the immune response to the pneumonia vaccine (PCV-13) in older adults, and if this effect is affected by the healthy gut bacteria.
Contact: Grace Lee, PhD | 210-450-8097
SPINAL CORD INJURY AND MYRBETRIQ®
Treatment of Spinal Cord Injury patients for neurogenic bladder: An open label, pilot study of anticholinergic agent vs. mirabegron (MYRBETRIQ ®) to evaluate cognitive impact and efficacy (SCIMYR)
This study is funded through a grant from the National Institutes of Health/National Institute on Aging to UT Health San Antonio’s Claude D. Pepper Older Americans Independence Center so that the researchers can conduct the study.
Currently Recruiting
This clinical trial is designed to collect preliminary data on effects of treatment with anti-cholinergic medication versus mirabegron and the impact on cognition in humans with spinal cord injury and neurogenic bladder.
Contact: Barshop Clinical Research Call Center | 210-450-0020
SARA-INT
Safety and Efficacy of BIO-101 175 mg b.i.d. and 350 mg b.i.d. 26-week oral administration to patients suffering from age-related SARcopenia (muscle loss), including sarcopenic obesity, Aged less than greater than or equal to 65 years and at risk of mobility disability. A double-blind, placebo controlled, randomized INTerventional Clinical Trial.
The funding for this study is provided to UT Health San Antonio by the industry sponsor (Biophytis) through the clinical research organization (ICON) which allows the researchers to conduct the study.
Currently Recruiting
The purpose of this study is to evaluate an oral drug given for 26 weeks for the treatment of muscle loss in older adults.
Contact: Barshop Clinical Research Call Center │ (210) 450-0020
The Effects of Nicotinamide Adenine Dinucleotide (NAD) on Brain Function and Cognition (NAD)
Funded by a grant from the National Institute of Health Older American Independent Center
Closed to Recruitment
Subjects previously diagnosed with or without Mild Cognitive Impairment (MCI) by the Texas Alzheimer’s Research Study (TARC). Study involve 5 visits and intermittent phone contact by study coordinator. Participants are randomized to Vitamin B3 /Placebo and follow incremental dose increases weeks 1-3 then wk. 4-10 are on standardized dose till study completion.
Contact: Barshop Clinical Research Call Center | 210-450-0020
Location: STVHCS Audie L. Murphy VA Hospital